gliclazide has been researched along with phenylalanine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujitani, S; Okazaki, K; Yada, T | 1 |
| Kawamori, R; Miwa, S; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S | 1 |
| Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P | 1 |
| Fujii, M; Inoguchi, T; Kobayashi, K; Maeda, Y; Morinaga, H; Nomura, M; Sasaki, S; Sawada, F; Takayanagi, R; Tsubouchi, H | 1 |
| Banu, H; Renuka, N; Vasanthakumar, G | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Fatehi, M; Lang, VY; Light, PE | 1 |
1 review(s) available for gliclazide and phenylalanine
| Article | Year |
|---|---|
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
3 trial(s) available for gliclazide and phenylalanine
| Article | Year |
|---|---|
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Topics: Adult; Cross-Over Studies; Cyclohexanes; Deoxyglucose; Diabetes Mellitus, Type 2; Gliclazide; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Malondialdehyde; Nateglinide; Phenylalanine; Prospective Studies; Serum Albumin; Thiobarbituric Acid Reactive Substances | 2004 |
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period; Treatment Outcome | 2006 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Safety; Time Factors | 2007 |
4 other study(ies) available for gliclazide and phenylalanine
| Article | Year |
|---|---|
The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition.
Topics: Animals; Calcium; Cyclohexanes; Cytosol; Electron Transport; Enzyme Inhibitors; Gliclazide; Glucokinase; Glucose; Hypoglycemic Agents; Islets of Langerhans; Mitochondria; Nateglinide; Oxidative Phosphorylation; Phenylalanine; Rats; Rats, Wistar; Sulfonylurea Compounds; Tolbutamide | 1997 |
Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.
Topics: Animals; Apoptosis; Cell Line; Cyclohexanes; Fluoresceins; Gliclazide; Glyburide; Hypoglycemic Agents; In Situ Nick-End Labeling; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; NADPH Oxidases; Nateglinide; Phenylalanine; Protein Kinase C; Reactive Oxygen Species; Sulfonylurea Compounds | 2008 |
Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Binding Sites; Biocatalysis; Catalytic Domain; Cytochrome P-450 CYP2C9; Enzyme Stability; Genotype; Gliclazide; Heme; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxylation; Hypoglycemic Agents; Molecular Dynamics Simulation; Mutation; Phenylalanine; Protein Binding; Protein Structure, Tertiary | 2011 |
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Topics: ATP-Binding Cassette Transporters; Chlorpropamide; Cyclohexanes; Diabetes Mellitus, Type 2; Gene Expression Regulation; Gliclazide; Glyburide; Haplotypes; Homozygote; Humans; Isoindoles; Nateglinide; Patch-Clamp Techniques; Phenylalanine; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Structure-Activity Relationship; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |